Jane Huang

Director at 858 Therapeutics

About

Dr. Huang is the President and Chief Medical Officer of Prelude Therapeutics. Prior to joining Prelude, she served as Chief Medical Officer of Hematology at BeiGene, Ltd., where she created a global development organization encompassing clinical pharmacology to global product safety and had strategic oversight of the development of five hematology medicines. During her tenure with BeiGene, she oversaw the approval of zanubrutinib in three diseases spanning more than 45 countries and was responsible for the first approval of tislelizumab in Hodgkin’s lymphoma. Prior to joining BeiGene in 2016, Dr. Huang served as Vice President, Clinical Development at Acerta Pharma, where she oversaw global clinical development of the BTK inhibitor, acalabrutinib. Prior to this, she worked at Genentech, where she played a leading role in drug development programs for multiple therapies throughout all stages of development, including, Rituxan, Avastin, Kadcyla, Venclexta and Gazyva.


Dr. Huang holds a Bachelor of Science degree in Biological Sciences from Stanford University and an M.D. from University of Washington School of Medicine. She is board certified in hematology, oncology, and internal medicine, and she completed her residency in Internal Medicine and fellowships in Hematology and Oncology at Stanford University.

Timeline

  • Director

    Current role

The Org
helps you hire
great candidates
It takes less than ten minutes to set up your company page.
It’s free to use - try it out today.